TAXOTERE (Docetaxel)
Originator taxoid antineoplastic agent for breast, lung, prostate, gastric, and head and neck cancer
TAXOTERE is the originator brand of docetaxel, a taxoid antineoplastic (anticancer) medicine first developed from an extract of the European yew tree (Taxus baccata). Approved by the European Medicines Agency (EMA) in 1995 and by the U.S. Food and Drug Administration (FDA) in 1996, TAXOTERE has become a cornerstone of modern oncology, used to treat breast, lung, prostate, gastric, and head and neck cancers. It works by disrupting the internal skeleton of rapidly dividing cancer cells, halting their division and triggering programmed cell death. TAXOTERE is given as an intravenous infusion in a hospital setting under the supervision of a specialist oncology team.
Quick Facts
Key Takeaways
- TAXOTERE is the original branded form of docetaxel, a taxoid chemotherapy approved for breast, lung, prostate, gastric, and head and neck cancers.
- It must be administered intravenously in a hospital or specialized infusion center by staff experienced in cancer chemotherapy, typically once every three weeks.
- Mandatory premedication with oral corticosteroids (e.g., dexamethasone) starting the day before each infusion significantly reduces hypersensitivity reactions and fluid retention.
- The most common side effects are neutropenia, anemia, hair loss, mouth sores, diarrhea, fluid retention, and fatigue; regular blood tests and clinical monitoring are essential.
- TAXOTERE is metabolized by CYP3A4 and interacts with many common drugs (e.g., ketoconazole, rifampicin, St. John's wort); patients should disclose all medications and supplements to their oncology team.
What Is TAXOTERE and What Is It Used For?
TAXOTERE contains the active substance docetaxel (as trihydrate), a semi-synthetic taxoid antineoplastic agent derived from 10-deacetylbaccatin III, a precursor extracted from the needles of the European yew tree (Taxus baccata). It belongs to the same broader drug family as paclitaxel but has a distinct clinical profile, including higher affinity for microtubules and a different toxicity pattern. TAXOTERE was first approved in the European Union in 1995 and in the United States in 1996, and it has remained a foundational chemotherapy in oncology ever since. The ATC classification code is L01CD02, identifying it as a taxane antineoplastic agent.
At the cellular level, docetaxel works by binding to the beta-tubulin subunit of microtubules, the dynamic "internal skeleton" that cells use for transport, shape maintenance, and chromosome separation during mitosis (cell division). By promoting the assembly of tubulin into stable microtubules and simultaneously inhibiting their disassembly, docetaxel effectively freezes the mitotic spindle. Cancer cells arrested in mitosis cannot complete division and are eliminated through apoptosis (programmed cell death). Because cancer cells divide much more rapidly than most normal tissues, they are particularly vulnerable to this mechanism, although some fast-turnover normal tissues (such as bone marrow, hair follicles, and the digestive tract lining) are also affected, which explains many of the drug's characteristic side effects.
TAXOTERE is licensed for a broad range of indications in adult oncology. In breast cancer, it is used both in the adjuvant setting (after surgery for localized disease, with or without lymph node involvement) and in locally advanced or metastatic disease. As adjuvant therapy for operable node-positive breast cancer, it is combined with doxorubicin and cyclophosphamide (the TAC regimen). In HER2-positive metastatic breast cancer, it may be given with trastuzumab, and in pretreated metastatic disease it can be combined with capecitabine. Monotherapy is an option after failure of prior cytotoxic therapy that included an anthracycline or an alkylating agent.
In non-small cell lung cancer (NSCLC), TAXOTERE is indicated as monotherapy for locally advanced or metastatic disease after failure of prior chemotherapy, and as first-line treatment for unresectable, locally advanced, or metastatic NSCLC in combination with cisplatin in chemotherapy-naive patients. For metastatic castration-resistant prostate cancer, docetaxel in combination with prednisone or prednisolone was the first chemotherapy shown to prolong survival in pivotal trials (TAX 327 and SWOG 9916) and remains a standard option. It is also approved for hormone-sensitive metastatic prostate cancer in combination with androgen deprivation therapy based on evidence from the CHAARTED and STAMPEDE trials.
In gastric adenocarcinoma (including adenocarcinoma of the gastroesophageal junction) that has not been previously treated with chemotherapy, TAXOTERE is combined with cisplatin and 5-fluorouracil (the DCF regimen). In squamous cell carcinoma of the head and neck, it is used as induction chemotherapy with cisplatin and 5-fluorouracil (TPF regimen) before definitive radiotherapy or chemoradiotherapy in locally advanced disease. Off-label and combination uses continue to evolve as new evidence emerges, always under the guidance of an oncology specialist working within approved clinical protocols.
TAXOTERE is supplied as a sterile concentrate for solution for infusion. The package insert specifies strengths of 20 mg/0.5 mL (the more concentrated, one-vial formulation that does not require a separate solvent) and 20 mg/1 mL (the historical two-vial presentation supplied with a separate solvent vial). Larger presentations (80 mg/2 mL, 80 mg/4 mL, and 160 mg/8 mL) are also available in some markets. All forms contain polysorbate 80 and ethanol as excipients and must be prepared and administered by trained healthcare staff in a hospital setting.
What Should You Know Before Taking TAXOTERE?
TAXOTERE is a potent cytotoxic medicine that must only be prescribed and administered by or under the direct supervision of a qualified physician experienced in the use of anticancer chemotherapy. A comprehensive medical assessment is performed before therapy begins, including a review of previous cancer treatments, concurrent medications, relevant comorbidities (especially cardiac, pulmonary, hepatic, and renal conditions), and laboratory tests such as a full blood count, liver function tests, renal function, and sometimes cardiac evaluation. This baseline evaluation is repeated before each cycle to ensure treatment can proceed safely.
Contraindications
TAXOTERE must not be used in patients with known hypersensitivity (allergy) to docetaxel or to any of the excipients in the formulation, particularly polysorbate 80, which is the most common cause of infusion-related hypersensitivity reactions. Patients who have experienced severe allergic reactions to paclitaxel (a related taxoid) should inform their oncologist, because cross-reactivity between taxoids is possible and any subsequent reaction could be more severe.
TAXOTERE is contraindicated in patients whose baseline neutrophil count is less than 1,500 cells/mm³. Neutrophils are a subtype of white blood cells essential for defense against bacterial and fungal infections. Treating a patient who is already neutropenic creates an unacceptable risk of severe and potentially life-threatening infections, including febrile neutropenia and sepsis. The medicine must also not be given to patients with severe hepatic (liver) impairment, because docetaxel is primarily metabolized by the liver, and impaired liver function can cause dangerously high drug concentrations and markedly increased toxicity. In these patients, alternative treatments or modified regimens are considered on a case-by-case basis.
Additional contraindications include pregnancy and breastfeeding unless the benefit to the mother clearly outweighs the risk to the fetus or infant (see Pregnancy and Breastfeeding below). TAXOTERE is also contraindicated in patients with active uncontrolled severe infections.
Warnings and Precautions
Hematologic toxicity, particularly neutropenia, is the most important dose-limiting toxicity of docetaxel. The neutrophil nadir (lowest point) typically occurs around day 7 after infusion, with recovery usually by day 15–21. A complete blood count must therefore be performed before each cycle. Granulocyte colony-stimulating factor (G-CSF) support may be offered in high-risk regimens, in patients who have already developed febrile neutropenia, or in combination chemotherapy with a high risk of bone marrow suppression. Patients should report fever (especially above 38°C / 100.4°F), chills, sore throat, cough, shortness of breath, painful urination, or any sign of infection immediately.
Hypersensitivity reactions can occur within minutes of starting the first or second infusion. Severe reactions include generalized rash, hypotension, bronchospasm, angioedema, or, rarely, anaphylaxis. All patients receive mandatory corticosteroid premedication (see below) and are closely monitored during infusions. If a severe reaction occurs, the infusion is immediately stopped and appropriate supportive treatment administered. Patients who have experienced a severe hypersensitivity reaction should not be rechallenged with docetaxel.
Fluid retention is a cumulative, dose-dependent side effect characterized by peripheral edema (swelling of the legs and feet), weight gain, and, less commonly, pleural effusion, pericardial effusion, or ascites. Corticosteroid premedication significantly reduces the incidence and severity. Fluid retention generally resolves slowly after treatment is discontinued.
- Fever above 38°C (100.4°F), chills, or any sign of infection – may indicate febrile neutropenia, a medical emergency
- Severe abdominal pain, persistent vomiting, bloody diarrhea, or rectal bleeding – may indicate serious gastrointestinal injury, colitis, or intestinal perforation
- Severe shortness of breath, persistent cough, or wheezing – may indicate interstitial lung disease or anaphylaxis
- Blistering, peeling, or bleeding of the skin, mouth, eyes, or genitals – may indicate Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)
- Irregular or rapid heartbeat, chest pain, or fainting – may indicate cardiac arrhythmia or heart failure
- Sudden unilateral leg swelling, chest pain, or sudden shortness of breath – may indicate deep vein thrombosis or pulmonary embolism
- Blurred vision or vision loss – requires urgent ophthalmologic assessment (cystoid macular edema has been reported)
Cardiac safety warrants specific attention. Docetaxel has been associated with ventricular arrhythmias, conduction abnormalities, heart failure (especially in combination with anthracyclines such as doxorubicin), and rare cases of myocardial infarction. Patients with known cardiovascular disease should be evaluated before treatment, and left ventricular ejection fraction may be monitored when cardiotoxic combinations are used. Patients should report new or worsening symptoms such as palpitations, breathlessness, chest pain, or ankle swelling.
Pulmonary toxicity including interstitial lung disease, pneumonitis, and pulmonary fibrosis has been reported with docetaxel. Patients who develop new or worsening cough, breathlessness, or fever should be evaluated promptly with imaging and pulmonary function assessment. If drug-induced pneumonitis is confirmed, TAXOTERE must be permanently discontinued.
Severe cutaneous adverse reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis have been reported. Any new widespread rash, particularly with blistering, skin peeling, fever, or mucosal involvement, requires immediate discontinuation and urgent specialist evaluation. Milder cutaneous reactions, hand-foot syndrome (palmar-plantar erythrodysesthesia), and nail changes are more common and usually manageable with supportive care and dose adjustments.
Peripheral neuropathy is a dose-dependent toxicity manifesting as numbness, tingling, burning, or pain in the hands and feet. It usually improves slowly after treatment discontinuation but can be persistent or permanent in some patients. Dose reduction or discontinuation may be required for severe or functionally limiting neuropathy.
Tumor lysis syndrome, a potentially life-threatening metabolic disturbance caused by the rapid breakdown of tumor cells, has been reported rarely with docetaxel. Patients with high tumor burden, elevated uric acid, or renal impairment are at increased risk and may require prophylactic hydration, allopurinol, or rasburicase. Renal function should be monitored during treatment.
Pregnancy and Breastfeeding
TAXOTERE must not be used during pregnancy unless the potential benefit clearly outweighs the risk, because docetaxel has been shown to be embryotoxic and fetotoxic in animal studies and may cause serious harm to the developing fetus in humans. Women of childbearing potential must use highly effective contraception during treatment and for at least 6 months after the last dose. If pregnancy occurs during therapy, the treating physician must be informed immediately, and the patient should receive genetic counseling.
Male patients receiving TAXOTERE should avoid fathering a child during treatment and for at least 6 months after the final dose. Because docetaxel can affect male fertility and potentially cause permanent infertility, sperm cryopreservation before the start of therapy should be considered and discussed with all male patients of reproductive age.
Breastfeeding is contraindicated during TAXOTERE treatment because it is unknown whether docetaxel is excreted into human milk, and the potential for serious adverse reactions in the nursing infant cannot be excluded. Breastfeeding should be discontinued before beginning therapy.
Alcohol Content
The concentrate contains anhydrous ethanol as an excipient. Older two-vial formulations (20 mg/1 mL) contain approximately 50% v/v ethanol, meaning a 20 mg dose may deliver about 395 mg of alcohol. Newer one-vial formulations (20 mg/0.5 mL) contain considerably less ethanol, but the exact amount varies by manufacturer and strength. The alcohol content may be clinically relevant for patients with alcohol dependence, epilepsy, liver disease, brain injury, and for pregnant or breastfeeding women. It can also impair the ability to drive or operate machinery and may increase the sedative effect of other central nervous system depressants. Patients should ask their oncology pharmacy about the exact ethanol content of the formulation being used.
Use in Elderly Patients
TAXOTERE is used in older adults with appropriate dose consideration. In patients aged 65 years and older receiving combinations such as docetaxel plus capecitabine or docetaxel plus cisplatin and 5-fluorouracil, starting dose reductions may be required due to increased risk of severe toxicity, particularly febrile neutropenia, grade 3–4 diarrhea, and fluid retention. Performance status, comorbidities, organ function, and geriatric assessment should all inform treatment decisions rather than chronological age alone.
Renal and Hepatic Impairment
Docetaxel is primarily eliminated by hepatic metabolism and biliary excretion, with less than 10% excreted unchanged in urine. Dose adjustments are therefore driven by liver function rather than kidney function. Patients with mild elevations in liver enzymes or bilirubin require dose reduction, and severe hepatic impairment is a contraindication. Routine dose adjustment for renal impairment is generally not required, but clinical judgment is necessary in patients with very severe renal dysfunction or on dialysis.
How Does TAXOTERE Interact with Other Drugs?
Drug–drug and drug–food interactions with TAXOTERE are clinically important because docetaxel is extensively metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. Concomitant medicines that inhibit or induce CYP3A4 can significantly modify plasma concentrations of docetaxel, translating into increased toxicity or reduced therapeutic efficacy. Patients should always inform their oncologist and pharmacist about all medicines taken, including those purchased without prescription, vitamins, herbal remedies, and recreational substances, before starting TAXOTERE and whenever a new medicine is introduced during treatment.
Major Interactions
Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, ritonavir, indinavir, and cobicistat can markedly reduce docetaxel clearance. Coadministration can increase the area under the concentration-time curve (AUC) by 2- to 3-fold, substantially increasing the risk of severe neutropenia, mucositis, diarrhea, and other dose-related toxicities. Wherever possible, these combinations should be avoided; if unavoidable, clinicians may consider dose reduction of docetaxel (commonly by 50%) and enhanced monitoring.
Strong CYP3A4 inducers such as rifampicin, rifabutin, phenytoin, carbamazepine, oxcarbazepine, phenobarbital, efavirenz, etravirine, and the herbal supplement St. John's wort (Hypericum perforatum) can substantially reduce docetaxel exposure, potentially compromising the chance of a clinical response. Patients should disclose all herbal products and over-the-counter supplements, because St. John's wort is commonly used without medical supervision. When strong inducers cannot be avoided, dose adjustments may be considered, although robust prospective data are limited.
Combination chemotherapy with other cytotoxic agents (e.g., cisplatin, carboplatin, doxorubicin, cyclophosphamide, capecitabine, 5-fluorouracil, trastuzumab) is commonly used intentionally, but the overlapping myelotoxicity, mucosal toxicity, neurotoxicity, and cardiotoxicity require careful scheduling and sometimes modified doses. Order of administration can matter: for example, docetaxel should generally be given before cisplatin in DCF regimens to avoid increased clearance of docetaxel when given after cisplatin.
Moderate and Minor Interactions
Moderate CYP3A4 inhibitors such as erythromycin, diltiazem, verapamil, fluconazole, and grapefruit juice can also increase docetaxel exposure to a lesser extent. Grapefruit and grapefruit juice, Seville oranges, and pomelos should be avoided throughout the treatment period. Moderate inducers such as bosentan, modafinil, and nevirapine can reduce docetaxel plasma concentrations; close monitoring for reduced efficacy is prudent if these cannot be discontinued.
Because TAXOTERE contains ethanol, additive effects with other CNS depressants (benzodiazepines, opioids, some antihistamines, muscle relaxants, and alcoholic beverages) should be anticipated. Driving and operation of machinery are best avoided on infusion days.
| Interacting Drug / Class | Effect on Docetaxel | Clinical Significance | Recommendation |
|---|---|---|---|
| Ketoconazole, itraconazole, voriconazole | Markedly increased levels (strong CYP3A4 inhibition) | Major – severe toxicity risk | Avoid combination; if unavoidable, reduce docetaxel dose and monitor closely |
| Clarithromycin, telithromycin | Increased levels (strong CYP3A4 inhibition) | Major – increased toxicity risk | Avoid; consider azithromycin as alternative if a macrolide is required |
| Ritonavir, other protease inhibitors, cobicistat | Markedly increased levels (strong CYP3A4 inhibition) | Major – severe toxicity risk | Avoid; switch antiretroviral regimen in consultation with HIV specialist |
| Erythromycin | Increased levels (moderate CYP3A4 inhibition) | Moderate | Monitor closely; consider alternatives |
| Grapefruit juice, Seville oranges, pomelo | Increased levels (intestinal CYP3A4 inhibition) | Moderate | Avoid throughout treatment |
| Rifampicin, rifabutin | Markedly decreased levels (strong CYP3A4 induction) | Major – reduced efficacy | Avoid combination; if unavoidable, consider dose increase with close monitoring |
| Phenytoin, carbamazepine, phenobarbital | Decreased levels (CYP3A4 induction) | Major – potentially reduced efficacy | Consider non-inducing anticonvulsants (e.g., levetiracetam) where appropriate |
| St. John's wort (Hypericum perforatum) | Decreased levels (CYP3A4 induction) | Major – reduced efficacy | Discontinue at least 2 weeks before starting treatment |
| Live vaccines (e.g., MMR, varicella, yellow fever) | Risk of disseminated vaccine-strain infection due to immunosuppression | Major – safety risk | Avoid during treatment and for at least 6 months after last dose |
| Warfarin and other anticoagulants | Altered coagulation due to chemotherapy effects and drug–protein binding | Moderate | Monitor INR more frequently; adjust anticoagulant dose as needed |
This list is not exhaustive; medicines not mentioned here can still interact with TAXOTERE. The oncology team will perform a full medication review before the first infusion and at each subsequent cycle. Patients are strongly encouraged to keep an up-to-date list of all their medicines and supplements and to show it to every healthcare professional they consult.
What Is the Correct Dosage of TAXOTERE?
TAXOTERE must only be administered by or under the direct supervision of an oncologist with extensive experience in cytotoxic chemotherapy, in a facility equipped to manage infusion reactions and cytotoxic drug complications. The dose is individualized using the patient's body surface area (BSA), calculated from height and weight in square meters (m²). Before each cycle, the oncology team reviews laboratory results (full blood count, liver enzymes, bilirubin) and clinical status (performance, prior toxicities) to decide whether to proceed, reduce the dose, or delay treatment.
Dosage by Cancer Type
| Cancer Type | Docetaxel Dose | Combination Agents | Cycle Interval |
|---|---|---|---|
| Breast cancer (advanced/metastatic, monotherapy) | 75–100 mg/m² | Single agent | Every 3 weeks |
| Early breast cancer (adjuvant, TAC) | 75 mg/m² | Doxorubicin 50 mg/m² + Cyclophosphamide 500 mg/m² | Every 3 weeks (6 cycles) |
| HER2-positive metastatic breast cancer | 100 mg/m² | Trastuzumab | Every 3 weeks |
| Metastatic breast cancer (pretreated) | 75 mg/m² | Capecitabine 1,250 mg/m² twice daily (days 1–14) | Every 3 weeks |
| NSCLC (second-line monotherapy) | 75 mg/m² | Single agent | Every 3 weeks |
| NSCLC (first-line with cisplatin) | 75 mg/m² | Cisplatin 75 mg/m² | Every 3 weeks |
| Metastatic castration-resistant prostate cancer | 75 mg/m² | Prednisone 5 mg twice daily | Every 3 weeks |
| Hormone-sensitive metastatic prostate cancer | 75 mg/m² | Androgen deprivation therapy ± prednisone | Every 3 weeks (6 cycles) |
| Gastric adenocarcinoma (DCF) | 75 mg/m² | Cisplatin 75 mg/m² + 5-Fluorouracil 750 mg/m²/day × 5 days | Every 3 weeks |
| Head & neck squamous cell carcinoma (TPF induction) | 75 mg/m² | Cisplatin 75 mg/m² + 5-Fluorouracil 750 mg/m²/day × 5 days | Every 3 weeks (4 cycles) |
Adults
In adults with adequate hematologic and hepatic function, the doses above are the conventional starting doses. Each infusion is diluted in 250 mL of 5% glucose or 0.9% sodium chloride and administered over approximately one hour through a peripheral or central venous access. TAXOTERE should not be given as a rapid intravenous push. The oncology team will observe the patient carefully during the first and second infusions, the periods of highest risk for hypersensitivity reactions. Most patients can be safely treated as outpatients, returning home after a post-infusion observation period.
Children
The safety and efficacy of TAXOTERE in children below 18 years of age have not been established. Docetaxel is not recommended for use in pediatric oncology outside of dedicated clinical trials. The specific formulation and excipient profile (particularly ethanol content) further limits its use in very young children. For pediatric patients who require chemotherapy, alternative age-appropriate regimens are used under the guidance of pediatric oncologists.
Elderly
In older adults (≥ 65 years), standard doses can generally be used with close monitoring of toxicity. In specific combinations, starting dose reductions are recommended:
- Docetaxel + capecitabine in patients ≥ 60 years: starting capecitabine dose reduced to 950 mg/m² twice daily
- DCF regimen (docetaxel + cisplatin + 5-fluorouracil) in elderly gastric cancer patients: dose reductions and/or alternative regimens (e.g., modified FOLFOX) should be considered given higher rates of febrile neutropenia and diarrhea
A formal geriatric assessment, including evaluation of comorbidities, polypharmacy, functional status, and nutritional status, supports individualized dosing decisions in this population.
Missed Dose
Because TAXOTERE is administered only in a healthcare setting, "missed doses" are not self-managed. If a scheduled infusion cannot take place due to low blood counts, infection, acute toxicity, or other reasons, the oncology team will typically delay the cycle by one to two weeks, repeat laboratory tests, and proceed when it is safe. Patients who cannot attend an appointment should contact their oncology clinic as early as possible so the cycle can be rescheduled and the overall treatment plan recalculated.
Overdose
There is no known specific antidote to docetaxel overdose. Overdose events are rare because administration is done by trained staff in a controlled setting. If an inadvertent overdose occurs, the likely consequences are severe bone marrow suppression, mucositis, and peripheral neurotoxicity. Management is supportive and includes intensive monitoring of vital signs, aggressive treatment of neutropenic infections (broad-spectrum antibiotics, possibly antifungals), blood product support, granulocyte colony-stimulating factor (G-CSF), and symptomatic measures for mucositis and neuropathy. Hemodialysis does not meaningfully remove docetaxel because of its high protein binding and large volume of distribution.
Premedication Protocol
Required Corticosteroid Premedication
Standard regimen (most indications): Oral dexamethasone 16 mg per day (e.g., 8 mg twice daily) starting the day before each TAXOTERE infusion and continued for 3 days total (day before, day of, and day after infusion). This protocol significantly reduces the incidence and severity of hypersensitivity reactions and cumulative fluid retention.
Prostate cancer regimen (with prednisone): Because the prednisone is already providing ongoing corticosteroid cover, a shorter schedule is used – dexamethasone 8 mg orally at 12 hours, 3 hours, and 1 hour before the docetaxel infusion.
Additional supportive measures may include prophylactic antiemetics, scalp cooling to reduce hair loss, peripheral neuropathy assessment tools, and, in high-risk combinations, primary G-CSF prophylaxis.
Dose Modifications
Dose reductions, cycle delays, or permanent discontinuation may be required based on individual tolerability. Common triggers include:
- Febrile neutropenia, neutrophils < 500 cells/mm³ for more than 7 days, or severe or persistent infection
- Grade 3–4 thrombocytopenia, bleeding, or severe anemia
- Grade 3–4 mucositis, diarrhea, or skin toxicity
- Grade 2 or higher peripheral neuropathy that persists into the next cycle
- Significant fluid retention refractory to diuretics and extended corticosteroid support
- Rising bilirubin, ALT, or AST above defined thresholds
Patients should keep a simple symptom diary between cycles noting fever, temperature readings, bowel habit, mouth soreness, skin changes, and any tingling or numbness. This information is invaluable for informed dosing decisions at each subsequent cycle.
What Are the Side Effects of TAXOTERE?
All medicines can cause side effects, although not everyone will experience them. With TAXOTERE, many side effects reflect the drug's cytotoxic mechanism and are common to the taxoid class. Severity depends on the dose, whether TAXOTERE is given alone or with other chemotherapy, and individual patient factors such as age, organ function, genetics (e.g., CYP3A4 variability), performance status, and cumulative exposure. Most side effects are manageable with premedication, supportive care, and timely dose modifications.
Infusion-related and hypersensitivity reactions can occur within minutes of starting the first or second infusion. Symptoms include flushing, rash, pruritus, chest tightness, back pain, chills, fever, tachycardia, or hypotension. Severe anaphylaxis is uncommon with appropriate premedication but remains a recognized risk. The infusion is paused or stopped at the first signs of a significant reaction, and the patient is treated and observed before any decision is made about rechallenge.
The table below groups the recognized side effects by how often they occur, using the MedDRA frequency categories used in European Medicines Agency product information.
Very Common
- Infections and neutropenia (low neutrophil count, most clinically significant hematologic toxicity)
- Anemia (low red blood cells) and thrombocytopenia (low platelets)
- Febrile neutropenia (fever with low neutrophils – medical emergency)
- Peripheral sensory and motor neuropathy (numbness, tingling, weakness in hands and feet)
- Anorexia (reduced appetite), altered taste, and weight changes
- Nausea, vomiting, diarrhea, constipation, abdominal pain, and dyspepsia
- Stomatitis and mucositis (mouth sores and inflammation)
- Alopecia (hair loss from scalp, body, eyebrows, and eyelashes)
- Nail changes including discoloration, ridging, and possible shedding
- Hand-foot syndrome (palmar-plantar erythrodysesthesia)
- Skin rashes and cutaneous reactions
- Myalgia (muscle pain), arthralgia (joint pain), bone pain, and back pain
- Peripheral edema and cumulative fluid retention
- Asthenia and fatigue
- Flu-like symptoms and low-grade fever
- Dyspnea (shortness of breath), cough, nasal congestion, and nosebleeds
- Hypersensitivity reactions (flushing, rash, hypotension, bronchospasm)
- Lacrimation (increased tearing) and conjunctivitis
- Amenorrhea and menstrual irregularities in premenopausal women
Common
- Oral candidiasis (fungal mouth infection)
- Dehydration
- Hypotension (low blood pressure) and hypertension
- Arrhythmia, tachycardia, palpitations
- Heart failure (especially with anthracycline combinations)
- Dizziness and headache
- Hearing loss or tinnitus
- Esophagitis (inflammation of the food pipe) and dysphagia
- Dry mouth
- Increased bleeding tendency (bruising, epistaxis)
- Elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and bilirubin
- Hyperglycemia and new-onset or worsening diabetes
- Hypokalemia, hypocalcemia, and hypophosphatemia
- Insomnia and anxiety
Uncommon
- Syncope (fainting)
- Cardiomyopathy
- Phlebitis and injection-site reactions (skin discoloration, inflammation, extravasation)
- Pleural and pericardial effusion
- Deep vein thrombosis and pulmonary embolism
- Acute myeloid leukemia or myelodysplastic syndrome (secondary hematologic malignancies, more commonly with combination regimens)
Rare
- Neutropenic enterocolitis (typhlitis) – potentially fatal inflammation of the small intestine
- Intestinal perforation and ischemic colitis
- Disseminated intravascular coagulation
Not Known / Post-Marketing
- Interstitial lung disease, pneumonitis, and pulmonary fibrosis
- Acute respiratory distress syndrome (ARDS)
- Ventricular arrhythmia, ventricular tachycardia, and conduction disturbances
- Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
- Acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS)
- Scleroderma-like skin changes
- Persistent or permanent alopecia after prolonged use
- Cystoid macular edema (blurred vision from retinal swelling)
- Lacrimal duct obstruction (canalicular stenosis)
- Tumor lysis syndrome
- Radiation recall reactions
- Hepatitis (sometimes severe in patients with pre-existing liver disease)
- Myositis and muscle damage with elevated creatine kinase
- Secondary solid tumors and non-Hodgkin lymphoma (in combination regimens)
Reporting suspected adverse reactions after a medicine is authorized is important because it allows continuous monitoring of the benefit-risk balance. Patients and healthcare professionals can report suspected adverse reactions directly to the national competent authority, for example the EMA EudraVigilance system in the European Union, the FDA MedWatch program in the United States, the MHRA Yellow Card Scheme in the United Kingdom, or an equivalent national pharmacovigilance body. Prompt reporting helps protect future patients.
How Should You Store TAXOTERE?
Because TAXOTERE is a hospital-administered cytotoxic medicine, storage and handling are carried out by trained pharmacy and nursing staff in accordance with international cytotoxic drug handling guidelines (e.g., ISOPP Standards of Practice, NIOSH, EU-OSHA). Patients are not dispensed TAXOTERE vials for home use. Nonetheless, understanding the basic storage principles can be reassuring for patients and caregivers.
Unopened vials of TAXOTERE concentrate should be stored at temperatures not exceeding 25°C (77°F) and kept in the original outer carton to protect from light. The medicine should not be used after the expiry date printed on the outer carton and vial label; the expiry date refers to the last day of the stated month. As with all medicines, TAXOTERE must be stored out of the sight and reach of children. Pharmacy staff should treat damaged or leaking vials as cytotoxic spills and follow local decontamination protocols.
Once a vial is opened or diluted, the infusion solution should ideally be used immediately. In-use chemical and physical stability of the final infusion (in 5% glucose or 0.9% sodium chloride) has been demonstrated for up to 6 hours at 25°C or up to 48 hours at 2–8°C when stored in non-PVC containers. The six-hour window includes the one-hour infusion time. From a microbiological safety perspective, immediate use is preferred unless preparation has taken place under validated aseptic conditions.
The TAXOTERE infusion solution is a supersaturated system and may crystallize over time, particularly if stored or handled outside recommended conditions. Any solution showing visible crystallization, precipitates, particles, or changes in color or clarity must not be administered and should be disposed of as cytotoxic waste in accordance with local institutional policies. Administration sets, bags, and unused concentrate are similarly managed as cytotoxic waste. Contaminated surfaces are decontaminated following hospital procedures, and healthcare staff wear personal protective equipment (gloves, gown, eye protection) during preparation and administration.
What Does TAXOTERE Contain?
Each milliliter of TAXOTERE concentrate for solution for infusion contains 40 mg of docetaxel in the 20 mg/0.5 mL one-vial formulation, or 20 mg of docetaxel in the 20 mg/1 mL formulation (both expressed as the trihydrate). Available presentations may include:
- 20 mg/0.5 mL – single-vial (ready-to-dilute) formulation with reduced ethanol content
- 20 mg/1 mL – historical two-vial formulation supplied with a separate solvent
- 80 mg/2 mL or 80 mg/4 mL – mid-size presentations
- 160 mg/8 mL – large-volume vial for higher-dose regimens
The excipients (inactive ingredients) typically include:
- Polysorbate 80 – a non-ionic surfactant that solubilizes docetaxel in the concentrate; a common cause of hypersensitivity reactions and the main reason corticosteroid premedication is mandatory
- Anhydrous ethanol – a co-solvent, present in varying amounts depending on the formulation (higher in older two-vial presentations, lower in the modern one-vial 20 mg/0.5 mL formulation)
- Citric acid – pH adjustment
- Macrogol (polyethylene glycol) 300 – included in certain one-vial formulations to replace part of the ethanol content
- Water for injections – where applicable in the solvent vial
The concentrate is a clear, pale yellow to brownish-yellow viscous solution. Before administration it is diluted further in 250 mL of 5% glucose or 0.9% sodium chloride infusion fluid so that the final concentration does not exceed 0.74 mg/mL, reducing the risk of precipitation. More than one vial may be needed to obtain the calculated dose; for example, a 140 mg dose would require withdrawal of 7 mL from the 20 mg/1 mL formulation.
TAXOTERE should be prepared under controlled, aseptic conditions in a vertical laminar-flow biosafety cabinet. Non-PVC infusion sets and non-DEHP tubing are recommended because the polysorbate 80 vehicle can leach plasticizers from standard PVC equipment. Visual inspection of the solution for particles and crystallization is performed before administration; any solution showing abnormalities must be discarded as cytotoxic waste. Full instructions for reconstitution, dilution, administration, and disposal are included in the manufacturer's Summary of Product Characteristics (SmPC) and Prescribing Information.
Frequently Asked Questions About TAXOTERE
TAXOTERE (docetaxel) is licensed for the treatment of several solid tumors: breast cancer (both early-stage adjuvant therapy and advanced/metastatic disease), non-small cell lung cancer (NSCLC), metastatic castration-resistant and hormone-sensitive prostate cancer, gastric adenocarcinoma, and squamous cell carcinoma of the head and neck. It may be used as a single agent or in combination with other chemotherapy drugs such as doxorubicin, cyclophosphamide, cisplatin, 5-fluorouracil, trastuzumab, capecitabine, or prednisone, depending on cancer type and stage.
The actual docetaxel infusion takes approximately one hour, given as an intravenous drip in a hospital or specialized outpatient infusion center. A full treatment visit normally takes several hours once you include pre-infusion blood tests, clinical review, premedications, the infusion itself, and a post-infusion observation period. The cycle is most commonly repeated every three weeks, but your oncologist may adjust the interval based on your response and tolerability.
Dexamethasone (a corticosteroid) is taken as a mandatory premedication starting the day before each TAXOTERE infusion. Its purpose is twofold: it significantly reduces the risk of severe hypersensitivity reactions caused primarily by the polysorbate 80 vehicle, and it limits the cumulative fluid retention that otherwise develops with repeated cycles. In prostate cancer regimens that already include daily prednisone, a shorter schedule of dexamethasone 8 mg given 12 hours, 3 hours, and 1 hour before infusion is used instead. Taking the premedication exactly as prescribed is one of the most important things patients can do to tolerate treatment well.
Hair loss (alopecia) is one of the most common side effects of TAXOTERE and affects the majority of patients. Loss usually starts within the first 2–4 weeks of treatment and can involve the scalp, eyelashes, eyebrows, and body hair. In most cases, hair begins to regrow within a few months after treatment ends, sometimes with a temporary change in color or texture. Cases of persistent or permanent thinning have been reported, particularly after multiple cycles or combination regimens. Scalp cooling during infusions (cold caps) can reduce hair loss in some patients and is offered in many oncology units. Wigs, headscarves, and other practical solutions can also be discussed with the oncology nurses.
On infusion days it is generally advisable not to drive. The ethanol content of the concentrate, combined with possible fatigue, dizziness, nausea, and the effects of premedications, can impair your reaction times and concentration. Between cycles, your ability to drive depends on whether you are experiencing lingering side effects such as peripheral neuropathy (numbness in the hands or feet) or significant fatigue. Always ask your oncologist or nurse whether it is safe to drive in your individual circumstances, particularly after the first cycle when the response to treatment is still being established.
Yes. Historically, TAXOTERE was supplied as a two-vial product with a solvent vial containing approximately 50% v/v ethanol, which meant a 20 mg dose delivered around 395 mg of alcohol (similar to about 10 mL of beer). Newer one-vial formulations (including 20 mg/0.5 mL) have been developed with reduced ethanol content, replacing part of the alcohol with macrogol. The exact amount of ethanol per dose varies with the formulation and strength used in your hospital, so it is worth asking your oncology pharmacist. The alcohol content is clinically important for patients with alcohol dependence, epilepsy, liver disease, brain injury, young children, and pregnant or breastfeeding women.
TAXOTERE is the original (originator) brand of docetaxel, developed and marketed by Sanofi. Since the expiration of data exclusivity, multiple generic docetaxel products have become available (for example, Docetaxel Accord, Docetaxel Teva, Docetaxel Kabi, and many others). These generics contain the same active substance and must demonstrate equivalent quality, efficacy, and safety to TAXOTERE. Excipient composition, ethanol content, vial size, and reconstitution instructions can differ between brands, so pharmacists and nurses always follow the specific product's Summary of Product Characteristics. Clinically, outcomes and indications are the same.
Grapefruit, grapefruit juice, Seville oranges, and pomelos should be avoided throughout TAXOTERE treatment because they inhibit the CYP3A4 enzyme and can raise docetaxel levels, increasing the risk of toxicity. Alcohol should be limited or avoided, particularly around infusion days, because of the ethanol content of the concentrate and potential additive sedation. Raw or undercooked foods (sushi, raw eggs, unpasteurized dairy, rare meats, unwashed salads) may be discouraged during periods of neutropenia due to infection risk. Herbal remedies, especially St. John's wort, can reduce docetaxel efficacy and should be avoided. A registered dietitian or oncology nurse can give personalized advice tailored to your regimen and blood counts.
References
This article is based on peer-reviewed medical literature and authoritative regulatory sources:
- European Medicines Agency (EMA). TAXOTERE – Summary of Product Characteristics (SmPC). EMA/CHMP. Available at: www.ema.europa.eu. Accessed January 2026.
- U.S. Food and Drug Administration (FDA). TAXOTERE (docetaxel) Prescribing Information. Sanofi-Aventis. Available at: www.fda.gov.
- Herbst RS, Khuri FR. Mode of action of docetaxel – a basis for combination with novel anticancer agents. Cancer Treatment Reviews. 2003;29(5):407–415. doi:10.1016/S0305-7372(03)00097-5
- Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. New England Journal of Medicine. 2005;352(22):2302–2313. doi:10.1056/NEJMoa043681
- Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer (TAX 327). New England Journal of Medicine. 2004;351(15):1502–1512. doi:10.1056/NEJMoa040720
- Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer (CHAARTED). New England Journal of Medicine. 2015;373(8):737–746. doi:10.1056/NEJMoa1503747
- Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil for advanced gastric cancer (V-325 trial). Journal of Clinical Oncology. 2006;24(31):4991–4997. doi:10.1200/JCO.2006.06.8429
- Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer (TAX 323). New England Journal of Medicine. 2007;357(17):1695–1704. doi:10.1056/NEJMoa071028
- ESMO Clinical Practice Guidelines: Breast Cancer, Lung Cancer, Prostate Cancer, Gastric Cancer, Head and Neck Cancers. European Society for Medical Oncology. Available at: www.esmo.org/guidelines.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Available at: www.nccn.org.
- World Health Organization. WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO; 2023. Available at: www.who.int.
- British National Formulary (BNF). Docetaxel monograph. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk.
- Baker J, Ajani J, Scotté F, et al. Docetaxel-related side effects and their management. European Journal of Oncology Nursing. 2009;13(1):49–59. doi:10.1016/j.ejon.2008.10.003
- Engels FK, Mathot RA, Verweij J. Alternative drug formulations of docetaxel: a review. Anti-Cancer Drugs. 2007;18(2):95–103. doi:10.1097/CAD.0b013e3280113338
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, which includes board-certified specialists in oncology, clinical pharmacology, and evidence-based medicine. All content is produced in accordance with international medical guidelines (EMA, FDA, ESMO, NCCN, WHO) and follows the GRADE framework for grading the strength of evidence.
All medical information is reviewed by oncology specialists with direct clinical experience in solid tumor chemotherapy, ensuring accuracy and relevance to current treatment standards and multidisciplinary cancer care.
Content is based on Level 1A evidence from systematic reviews, randomized controlled trials, EMA and FDA approved product information, and internationally recognized clinical practice guidelines (ESMO, NCCN, ASCO).
iMedic receives no funding from pharmaceutical companies, medical device manufacturers, or any party with a commercial interest in the products discussed. All content is independently produced and free from advertising. Our editorial policy, review process, and conflict-of-interest statements are publicly available on our Editorial Standards page.